Securing and utilizing public research grants
First written in FY2019. 11 of 18 entries say "Restated". Latest entry: FY2026.
0 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The main components of non-operating income were ¥72.167 million in subsidy income, ¥42.618 million in interest received and ¥4.040 million in dividends received.」
The Company recorded ¥72.167 million in subsidy income related to public research grants and other sources, demonstrating in its financial results its use of public funds for research and development. - 2026-06-18AdvancedOccurring Fact
「During the accounting period for the fiscal year ended July 2026, receipt was confirmed for ¥12,133 thousand in subsidies for fiscal 2024 and ¥59,973 thousand in subsidies for fiscal 2025, which were recorded as non-operating income.」
For AMED subsidies related to SR-GT1, the company progressed from reporting possible receipt to confirming receipt and recognizing as income the subsidies for fiscal 2024 and fiscal 2025. - FY2026-H1RestatedAnnual report
「Under this research project, it is possible to receive a subsidy from AMED equivalent to two-thirds of the expenses incurred, with the potential to receive a total grant of up to ¥179 million over the 3-year period from FY2024 through FY2026 (ending March 2027).」
The policy of using public research grants, including AMED grants, for research and development and the potential for up to ¥179 million in funding for SR-GT1 are being reaffirmed. - FY2025RestatedAnnual report
「We recognise that continuing to actively secure and use public research grants is an important management priority for the company.」
The policy of continuously securing and using public research grants to help cover the costs of exploratory research and other activities is being reaffirmed. - FY2025-H1AdvancedAnnual report
「Under this research project, it is possible to receive a subsidy from AMED equivalent to two-thirds of the expenses incurred, with the potential to receive a total grant of up to ¥179 million over 3 years.」
The research on SR-GT1 was selected for an AMED FY2024 programme, with the potential to receive a subsidy covering two-thirds of expenses incurred, up to a total of ¥179 million over 3 years. - FY2024RestatedAnnual report
「We recognise that continuing to actively secure and use public research grants is an important management priority for the company.」
The policy of continuously securing and using public research grants to help cover the costs of exploratory research is being reaffirmed. - FY2024-Q3RestatedAnnual report
「In addition, from April 2022, we have been participating as a joint research company in the FY2022 Practical Research Project for Rare/Intractable Diseases conducted by the Japan Agency for Medical Research and Development (AMED).」
The company's participation as a joint research company in AMED's Practical Research Project for Rare/Intractable Diseases is being reaffirmed. - FY2024-Q1RestatedAnnual report
「In addition, from April 2022, we have been participating as a joint research company in the FY2022 Practical Research Project for Rare/Intractable Diseases conducted by the Japan Agency for Medical Research and Development (AMED).」
The company's participation as a joint research company in AMED's Practical Research Project for Rare/Intractable Diseases is being reaffirmed. - FY2023-Q1RestatedAnnual report
「In addition, from April 2022, we have been participating as a joint research company in the FY2022 Practical Research Project for Rare/Intractable Diseases conducted by the Japan Agency for Medical Research and Development (AMED).」
The company's participation as a joint research company in AMED's Practical Research Project for Rare/Intractable Diseases is being reaffirmed. - FY2022RestatedAnnual report
「We recognise that continuing to actively secure and use public research grants is an important management priority for the company.」
The policy of continuously securing and using public research grants to help cover the costs of exploratory research is being reaffirmed. - FY2022-Q3AdvancedAnnual report
「From April 2022, we will participate as a joint research company in the FY2022 Practical Research Project for Rare/Intractable Diseases conducted by the Japan Agency for Medical Research and Development (AMED).」
The company was confirmed as a joint research company in AMED's FY2022 Practical Research Project for Rare/Intractable Diseases, demonstrating a new record of selection for public research funding and joint research. - FY2021-Q2RestatedAnnual report
「Redasemtide was selected for the FY2020 "Drug Development for Novel Coronavirus Disease (COVID-19)" programme (third call for applications) conducted by the Japan Agency for Medical Research and Development (AMED).」
The company's selection for AMED's COVID-19 drug development programme is being reaffirmed. - FY2021-Q1RestatedAnnual report
「Redasemtide was selected for the FY2020 "Drug Development for Novel Coronavirus Disease (COVID-19)" programme (third call for applications) conducted by the Japan Agency for Medical Research and Development (AMED).」
The company's selection for AMED's COVID-19 drug development programme is being reaffirmed. - FY2020AdvancedAnnual report
「We were selected for the FY2020 "Drug Development for Novel Coronavirus Disease (COVID-19)" programme (third call for applications) conducted by the Japan Agency for Medical Research and Development (AMED), and aim to proceed to the launch of a clinical trial for patients with COVID-19 pneumonia.」
As a new public research grant, the company was selected for AMED's FY2020 programme for the development of COVID-19 treatments. - FY2020-Q3RestatedAnnual report
「During the fiscal year, a research theme related to this project was selected for the FY2017 Strategic Core Technology Advancement Program operated by the Small and Medium Enterprise Agency, enabling us to obtain a research grant. In addition, funding raised through a public offering accompanying our new listing enabled us to further increase investment in this project and establish a foundation for accelerating research and development.」
The company's record of securing public research grants and its explanation of using funds raised through the listing for research and development are being reaffirmed. - FY2020-Q2RestatedAnnual report
「During the fiscal year, a research theme related to this project was selected for the FY2017 Strategic Core Technology Advancement Program operated by the Small and Medium Enterprise Agency, enabling us to obtain a research grant」
The company's track record of securing a public research grant for the discovery of new candidate compounds is being reaffirmed. - FY2020-Q1AdvancedAnnual report
「During the fiscal year, a research theme related to this project was selected for the FY2017 Strategic Core Technology Advancement Program operated by the Small and Medium Enterprise Agency, enabling us to obtain a research grant」
Concrete progress has been reported for the new-candidate-compound discovery project, including the selection of its research theme for a public programme and the award of a research grant. - FY2019First statedAnnual report
「As the number of new projects entering the exploratory research stage is expected to increase following the completion of the out-licensing of existing projects, we recognise that continuing to actively secure and use public research grants is an important management priority for the company.」
The company has indicated its policy of continuously securing and using public research grants to help cover the costs of exploratory research.